Mereo BioPharma Group plc Capital Reinvestment Ratio

Latest as of June 2021: 0.05x

Mereo BioPharma Group plc capital reinvestment ratio. Mereo BioPharma Group plc (MAH0) has a Capital Reinvestment Ratio of 0.05x as of June 2021, meaning it reinvests 0% of its operating cash flow (€4.95 Million) in capital expenditures (€267.50K). Check MAH0 cash reinvestment to operating cash ratio to assess the company's total reinvestment commitment from operating cash flow.

Capital Reinvestment Ratio

0.05x

Capex / Operating Cash Flow

Operating Cash Flow

€4.95 Million

EUR

Capital Expenditures

€267.50K

EUR

Data as of

Jun 2021

Most recent filing

Mereo BioPharma Group plc Capital Reinvestment Ratio by Year (None–None)

Mereo BioPharma Group plc capital reinvestment ratio by year from None to None. For the full cash flow conversion analysis, see Mereo BioPharma Group plc cash conversion from operations.

Year	Reinvestment Ratio	Operating CF (EUR)	Capital Expenditures	YoY Change

Capital Reinvestment Ratio = ABS(Capital Expenditures) / Operating Cash Flow